Form 4: Akero Therapeutics Executive Catriona Yale Executes Stock Options and Sells Shares Under 10b5-1 Plan

Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Catriona Yale, Chief Development Officer of Akero Therapeutics, executed transactions involving Akero Therapeutics, Inc. [AKRO] common stock.
• On October 30, 2024, Yale exercised options to acquire 4,515 shares at a price of $21.10 and sold the same amount of shares at a weighted-average price of $32.526, ranging from $32.50 to $32.60.
• On November 1, 2024, Yale exercised options to acquire 15,485 shares at a price of $21.10 and sold the same amount of shares at a weighted-average price of $32.619, ranging from $32.50 to $32.87.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan dated May 28, 2024.
• Following these transactions, Yale directly owns 74,158 shares of Akero Therapeutics common stock and holds options to purchase 41,781 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the executive's confidence in the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Industry Context

Insider transactions are common and closely monitored, especially in biotech companies like Akero Therapeutics, as they can provide insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the biotechnology sector like Madrigal Pharmaceuticals or Viking Therapeutics, to utilize 10b5-1 trading plans to manage their stock holdings.
• The details of these plans and the subsequent transactions are publicly disclosed through SEC filings, allowing investors to monitor insider activity.
• The size and frequency of these transactions can vary widely depending on the individual's compensation structure, personal financial planning, and company stock performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• However, the existence of a 10b5-1 plan mitigates concerns about insider information being used for personal gain.

Key Dates